Search Results - "Gallowitsch, H. J."

Refine Results
  1. 1

    Real-World Data for Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer (RELEVANT): A Retrospective Multicentric Analysis of Clinical Practice in Austria by Pirich, C., Gallowitsch, H. J., Hitzl, W., Raderer, M., Trummer, C., Sorko, S., Becherer, A., Sipos, B., Rendl, G., Ardelt, M.

    “…Background. Lenvatinib has proven efficacy in progressive, radioiodine- (RAI-) refractory thyroid cancer (TC). Dose reductions are commonly performed due to…”
    Get full text
    Journal Article
  2. 2

    Clinical outcome of radiosynoviorthesis: a meta-analysis including 2190 treated joints by KRESNIK, E, MIKOSCH, P, GALLOWITSCH, H J, JESENKO, R, JUST, H, KOGLER, D, GASSER, J, HEINISCH, M, UNTERWEGER, O, KUMNIG, G, GOMEZ, I, LIND, P

    Published in Nuclear medicine communications (01-07-2002)
    “…A variety of indications for radiosynoviorthesis have been reported in literature, but the clinical outcome differs and depends on the primary disease and the…”
    Get full text
    Journal Article
  3. 3
  4. 4

    Epidemiology of thyroid diseases in iodine sufficiency by Lind, P, Langsteger, W, Molnar, M, Gallowitsch, H J, Mikosch, P, Gomez, I

    Published in Thyroid (New York, N.Y.) (01-12-1998)
    “…Epidemiology of thyroid diseases in iodine-sufficient areas (ISA) deals with sporadic goiter, thyroid autoimmune diseases, and thyroid cancer. A comparison…”
    Get more information
    Journal Article
  5. 5

    Sentinel node SPECT-CT in breast cancer. Can we expect any additional and clinically relevant information? by Gallowitsch, H-J, Kraschl, P, Igerc, I, Hussein, T, Kresnik, E, Mikosch, P, Kohlfuerst, S, Hausegger, K, Lind, P

    Published in Nuclear medicine (2007)
    “…The AIM of this study was to determine the additional value of SPECT/CT in sentinel node scintigraphy in breast cancer. Furthermore, it was our question to…”
    Get more information
    Journal Article
  6. 6
  7. 7

    Value of ultrasound-guided fine-needle aspiration biopsy of thyroid nodules in an endemic goitre area by Mikosch, P, Gallowitsch, H J, Kresnik, E, Jester, J, Würtz, F G, Kerschbaumer, K, Unterweger, O, Dinges, H P, Lind, P

    Published in European journal of nuclear medicine (01-01-2000)
    “…The aim of this study was to determine the value, advantages and limitations of ultrasound-guided fine-needle aspiration biopsy (US-FNAB) in an endemic goitre…”
    Get full text
    Journal Article
  8. 8
  9. 9
  10. 10

    Thyroid hemiagenesis in an endemic goiter area diagnosed by ultrasonography: report of sixteen patients by Mikosch, P, Gallowitsch, H J, Kresnik, E, Molnar, M, Gomez, I, Lind, P

    Published in Thyroid (New York, N.Y.) (01-11-1999)
    “…During a period of 9 years, 71,500 patients underwent thyroid investigations at our department. Sixteen patients with thyroid hemiagenesis, 13 women and 3 men,…”
    Get more information
    Journal Article
  11. 11

    Is there a role for scintigraphic imaging of bone manifestations in Gaucher disease? A review of the literature by Mikosch, P, Kohlfürst, S, Gallowitsch, H J, Kresnik, E, Lind, P, Mehta, A B, Hughes, D A

    Published in Nuclear medicine (2008)
    “…Gaucher disease is the most prevalent inherited, lysosomal storage disease and is caused by deficient activity of the enzyme beta-glucocerebrosidase. Bone and…”
    Get more information
    Journal Article
  12. 12

    Thyroglobulin and Low-Dose Iodine-131 and Technetium-99m-Tetrofosmin Whole-Body Scintigraphy in Differentiated Thyroid Carcinoma by Gallowitsch, Hans Juergen, Mikosch, Peter, Kresnik, Ewald, Unterweger, Oliver, Gomez, Iris, Lind, Peter

    Published in The Journal of nuclear medicine (1978) (01-05-1998)
    “…Determination of thyroglobulin (Tg) levels, determined under endogenous thyroid-stimulating hormone stimulation after withdrawal of L-thyroxin treatment…”
    Get full text
    Journal Article
  13. 13

    Technetium-99m-Tetrofosmin Whole-Body Scintigraphy in the Follow-up of Differentiated Thyroid Carcinoma by Lind, Peter, Gallowitsch, Hans J, Langsteger, Werner, Kresnik, Ewald, Mikosch, Peter, Gomez, Iris

    Published in The Journal of nuclear medicine (1978) (01-03-1997)
    “…The purpose of this study was to evaluate prospectively the reliability of the new nonspecific tumor-searching tracer tetrofosmin in the postoperative…”
    Get full text
    Journal Article
  14. 14

    Receptor activator of nuclear factor κB ligand and osteoprotegerin in men with thyroid cancer by Mikosch, P., Igerc, I., Kudlacek, S., Woloszczuk, W., Gallowitsch, H. J., Kresnik, E., Stettner, H., Grimm, G., Lind, P., Pietschmann, P.

    Published in European journal of clinical investigation (01-08-2006)
    “…Background  Suppressive thyroid hormone therapy is generally a lifelong treatment for patients with differentiated thyroid cancer (DTC). However, long‐standing…”
    Get full text
    Journal Article
  15. 15

    Technetium-99m-MIBI Scintigraphy of Thyroid Nodules in an Endemic Goiter Area by Kresnik, Ewald, Gallowitsch, Hans-Jurgen, Mikosch, Peter, Gomez, Iris, Lind, Peter

    Published in The Journal of nuclear medicine (1978) (01-01-1997)
    “…Technetium-99m-methoxyisobutylisonitrile (MIBI) was introduced for myocardial imaging as an alternative to 201TI. According to biodistribution studies, MIBI…”
    Get full text
    Journal Article
  16. 16

    Comparison of FDG-PET and dynamic contrast-enhanced MRI in the evaluation of suggestive breast lesions by Heinisch, M, Gallowitsch, H.J, Mikosch, P, Kresnik, E, Kumnig, G, Gomez, I, Lind, P, Umschaden, H.W, Gasser, J, Forsthuber, E.P

    Published in Breast (Edinburgh) (01-02-2003)
    “…The aim of our study was a direct comparison of the ability of positron-emission tomograpy with FDG-PET and of magnetic resonance imaging (MRI) to determine…”
    Get full text
    Journal Article
  17. 17

    Bone metabolism in patients with differentiated thyroid carcinoma receiving suppressive levothyroxine treatment by Mikosch, P, Obermayer-Pietsch, B, Jost, R, Jauk, B, Gallowitsch, H J, Kresnik, E, Leb, G, Lind, P

    Published in Thyroid (New York, N.Y.) (01-04-2003)
    “…Patients with differentiated thyroid carcinoma (DTC) must receive suppressive levothyroxine (LT(4)) therapy for the rest of their lives. The literature,…”
    Get more information
    Journal Article
  18. 18

    Suppressive levothyroxine therapy has no significant influence on bone degradation in women with thyroid carcinoma: a comparison with other disorders affecting bone metabolism by Mikosch, P, Jauk, B, Gallowitsch, H J, Pipam, W, Kresnik, E, Lind, P

    Published in Thyroid (New York, N.Y.) (01-03-2001)
    “…The aim of this study was to examine different influences on bone degradation (estrogen status, thyroid function, parathyroid function, bone metastases) with…”
    Get more information
    Journal Article
  19. 19

    Unusual malabsorption of levothyroxine by Jauk, B, Mikosch, P, Gallowitsch, H J, Kresnik, E, Molnar, M, Gomez, I, Lind, P

    Published in Thyroid (New York, N.Y.) (01-01-2000)
    “…We report a 50-year-old woman, with overt hypothyroidism undergoing thyrotropin (TSH)-stimulating hormone suppressive levothyroxine (LT4) treatment after…”
    Get more information
    Journal Article
  20. 20

    Results of preoperative ultrasound guided fine needle aspiration biopsy of solitary thyroid nodules as compared with the histology. A retrospective analysis of 538 patients by Mikosch, P, Wartner, U, Kresnik, E, Gallowitsch, H J, Heinisch, M, Dinges, H P, Lind, P

    Published in Nuclear medicine (01-10-2001)
    “…The goal of this study was to assess the accuracy and limitations of ultrasound guided fine-needle aspiration biopsy (ug-FNAB) of solitary thyroid nodules. The…”
    Get more information
    Journal Article